Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2024-02-12 Delisting Announcement
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience Plc - Results of 2nd General Meeting
Delisting Announcement Classification · 1% confidence The document explicitly states it is a "SPECIAL RESOLUTION" passed at a "GENERAL MEETING" of ARIX BIOSCIENCE PLC on February 12, 2024. The content details the voluntary winding up of the company and the appointment of joint liquidators, referencing a Scheme of Reconstruction detailed in a Circular dated January 5, 2024. This type of formal resolution passed at a shareholder meeting, especially one concerning major corporate actions like winding up, aligns most closely with materials presented or voted upon at an Annual General Meeting (AGM) or an Extraordinary General Meeting (EGM). Since the resolution is a formal outcome of a general meeting, 'AGM-R' (AGM Information/Resolution) is the most appropriate classification, as it represents a formal outcome or material from such a meeting, distinct from a simple declaration of voting results (DVA) or a general regulatory filing (RNS).
2024-02-12 English
Scheme Effective
AGM Information Classification · 1% confidence The document announces that the 'Scheme Effective' date has been reached for the recommended all-share acquisition of Arix Bioscience PLC by RTW Biotech Opportunities Ltd, which was structured as a scheme of reconstruction and voluntary winding-up. Crucially, it reports the results of the 'Second General Meeting' where the resolution to place Arix into members' voluntary liquidation was passed. The document explicitly details the 'Number of votes cast at the General Meeting' (Votes For, Votes Against, Total Votes Validly Cast). This content directly relates to the official results from a shareholder vote at a general meeting. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to a corporate transaction (M&A/TAR), the primary focus and explicit data provided are the voting outcomes of the necessary shareholder meeting.
2024-02-12 English
Suspension of Trading in Shares
Delisting Announcement Classification · 1% confidence The document announces the suspension of trading in Arix Bioscience PLC shares in connection with a recommended all-share acquisition of its assets by RTW Biotech Opportunities Ltd, to be effected through a scheme of reconstruction and voluntary winding-up. This involves a major corporate transaction (acquisition/takeover) and subsequent procedural steps like a general meeting and trading suspension. This strongly aligns with the 'M&A Activity' definition (Code: TAR). Although it mentions a 'Second General Meeting' and the results will be announced later, the core subject is the acquisition proposal itself. It is not a DEF 14A (Remuneration), DVA (Voting Results), or AGM-R (AGM Presentation). Since it details the terms of the acquisition and the subsequent steps leading to the scheme, TAR is the most appropriate classification. The document ends with a standard regulatory dissemination notice, but the content is specific to M&A.
2024-02-12 English
Transaction Update
M&A Activity Classification · 1% confidence The document is an update regarding a recommended all-share acquisition of Arix Bioscience PLC by RTW Biotech Opportunities Ltd, structured as a scheme of reconstruction and voluntary winding-up. It specifically mentions the timetable for a 'Second General Meeting' where a resolution will be proposed as a special resolution, and details the consequences if passed (liquidation, asset transfer, share issuance, delisting). This relates to corporate actions, shareholder votes, and potential capital structure changes resulting from a takeover/merger proposal. 1. It is not a standard periodic report (10-K, IR, ER). 2. It is not a simple dividend notice (DIV) or management change (MANG). 3. It heavily involves a proposed acquisition/takeover ('RECOMMENDED ALL-SHARE ACQUISITION'). This strongly points towards M&A Activity (TAR). 4. It also discusses the upcoming General Meeting and the voting process related to the scheme, which touches upon AGM-R or DVA, but the core subject is the transaction itself. 5. Given the focus on the 'RECOMMENDED ALL-SHARE ACQUISITION' and the subsequent steps involving shareholder approval for the scheme of reconstruction, the most fitting primary category is Transaction in Assets/Takeover (TAR). 6. The document is a detailed announcement providing updates and an appendix with a timetable, making it a substantive filing, not just a brief RPA or RNS.
2024-02-07 English
Arix Bioscience Plc - Results of 1st General Meeting
Delisting Announcement Classification · 1% confidence The document is titled 'SPECIAL RESOLUTION' passed at a 'GENERAL MEETING' of ARIX BIOSCIENCE PLC on 29 January 2024. It details the approval and authorization for the Directors and Liquidators to implement a 'scheme of reconstruction' (the Scheme) involving a 'Transfer Agreement' and subsequent actions like applying for the 'delisting of the Shares'. This type of formal resolution passed at a shareholder meeting, especially one concerning major corporate restructuring (reconstruction/liquidation) and voting outcomes, strongly aligns with the purpose of an Annual General Meeting (AGM) or an Extraordinary General Meeting (EGM) where such resolutions are voted upon. Since the document is the formal record of the resolution passed at the meeting, it fits the 'AGM Information' category, which covers presentations and materials shared during the AGM. Although it mentions delisting (DLST), the primary content is the formal resolution itself from the meeting.
2024-01-29 English
Results of First General Meeting
AGM Information Classification · 1% confidence The document explicitly announces the 'Results of First General Meeting' held on 29-Jan-2024. It details that the 'Resolution proposed... was passed by the requisite majority of Shareholders' and provides a table showing the 'Number of votes cast at the General Meeting'. This content directly relates to the official results from a shareholder vote at a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a proxy solicitation (PSI) or AGM presentation (AGM-R), but the formal announcement of the outcome of a vote taken at that meeting.
2024-01-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.